Myung In Pharm, known for products like 'Igatang' and 'Making Q,' submitted a securities registration statement for listing on the Korea Composite Stock Price Index (KOSPI) on the 21st. Myung In Pharm plans to offer a total of 3.4 million shares in this listing. The entire amount will be newly issued shares without any existing share sales.
The desired offering price range (band) is 45,000 to 58,000 won, with the total offering amount expected to be between 153 billion and 197.2 billion won. The expected market capitalization after the listing is estimated to be between 657 billion and 846.8 billion won.
Demand forecasting for institutional investors to confirm the final offering price will take place from the 9th to the 15th of next month. General subscriptions are scheduled for the 18th and 19th of the same month. KB Securities is the lead underwriter.
Established in April 1985, Myung In Pharm is a pharmaceutical company specializing in central nervous system (CNS) treatments. It currently has over 200 types of treatments, 31 of which are standalone drugs, boasting the most comprehensive lineup in the country.
Myung In Pharm has expanded its market share by securing exclusive selling rights based on patent analysis and formulation technology. It has established a value chain that encompasses everything from research and development (R&D) to the manufacturing of active pharmaceutical ingredients (API) and the production and distribution of finished pharmaceuticals.
Last year, the consolidated sales and operating profit amounted to 269.4 billion won and 92.8 billion won, respectively. It achieved an operating profit margin in the 30% range for three consecutive years.
Lee Haeng-myeong, the CEO of Myung In Pharm, said, "We will use this IPO as a springboard to strengthen our competitiveness in overseas markets and create new business opportunities to support long-term growth."